Background-Exaggerated neointimal hyperplasia is considered as the primary mechanism for increased restenosis in patients with diabetes mellitus (DM) treated with bare-metal stent. However, the vessel response in DM and non-DM treated with different drug-eluting stents (DES) has not been systematically evaluated. Methods and Results-We investigated 3D intravascular ultrasound (postprocedure and 6 to 9 months) in 971 patients (267 with DM and 704 without DM) treated with sirolimus-(n=104), paclitaxel-(n=303), zotarolimus-(n=391), or everolimus-(n=173) eluting stents. Volumetric data were standardized by length as volume index (VI). At postprocedure, lumen VI at the stented segment was significantly smaller in DM than in non-DM, whereas vessel VI was similar between the 2 groups. At follow-up, neointimal obstruction and maximum cross-sectional narrowing (neointimal area/stent area) were not significantly different between the 2 groups with no interaction for the DES type. Consequently, lumen VI was smaller in DM than in non-DM at follow-up. In the reference segments, residual plaque burden at postprocedure was significantly greater in DM than in non-DM, although change in lumen VI was similar between the 2 groups. The arterial responses at the reference segments also showed no interaction for the DES type. Conclusions-DM and non-DM lesions showed similar vessel response in both in-stent and reference segments regardless of the DES type. In the DES era, the follow-up lumen in DM patients seems to be determined primarily by the smaller lumen at postprocedure rather than exaggerated neointima within the stent or plaque proliferation at the reference segments. 
W
hen treated with bare-metal stents (BMS), patients with diabetes mellitus (DM) are at particularly greater risk for restenosis and repeat revascularization procedures, 1 and are also at greater risk for other adverse clinical outcomes, including stent thrombosis, 2,3 myocardial infarction, and death. 1, 4 The primary mechanism for this increased restenosis is exaggerated neointimal hyperplasia. A more diffuse and accelerated form of atherosclerosis seen in DM patients, accompanied by small vessel size, long lesions, and greater plaque burden, may contribute to their well-documented increased risk of restenosis after stent implantation. 5, 6 Presently, the use of drug-eluting stents (DES) in percutaneous coronary interventions has improved outcomes in the treatment of coronary artery disease across many patient populations, including those with DM. Sirolimus, paclitaxel, zotarolimus, and everolimus-eluting stents, which are currently approved in the United States, have been shown to significantly reduce the rates of clinical restenosis compared with BMS, with similar effects observed in patients with and without DM. [7] [8] [9] [10] Intravascular ultrasound (IVUS) substudies evaluating vessel response in patients with and without DM, who were treated with DESs, have been reported yet had relatively small sample sizes, 11, 12 and the impact of various DESs on vessel response has not been systematically evaluated in the clinical setting. Therefore, the aim of this IVUS study was to evaluate vessel response in patients with and without DM who were treated with 4 different DES using large sample sizes.
Methods

Study Population
The original study data were pooled at both patient and lesion levels from 10 In the current study, only 1 lesion per patient was included. Among the trials included, only SPIRIT III was allowed to enroll 2 vessel disease based on the original study protocol, and 19 patients (6 with DM and 13 without DM) had 2 lesions (maximum 1 lesion per epicardial coronary artery) in this trial. In such cases, 1 lesion as the primary lesion based on original protocol was selected and the secondary lesion was excluded from the current study. The study design and 6-to 9-month results have been previously reported for those trials. 9, [13] [14] [15] [16] [17] [18] [19] From these studies, the results of standard angiographic and IVUS analysis from patients meeting the following criteria were pooled: (1) patients with stable or unstable angina who had undergone successful treatment with sirolimus-(SES; Cypher, Cordis, Miami Lakes, FL: n=104), paclitaxel-(PES; TAXUS Express, 2 Boston Scientific, Natick, MA: n=303), zotarolimus-(ZES; Endeavor, Medtronic CardioVascular, Santa Rosa, CA: n=391), and everolimus-(EES; XIENCE V, Abbott Vascular, Santa Clara, CA: n=173) eluting stents using standard stent implantation techniques without atheroablation; (2) complete volumetric (baseline and at 6-to 9-months mandated follow-up) IVUS studies; and (3) high-quality, automated pullback IVUS images within stented segments and up to 5 mm at adjacent segments outside each stent edge. All lesions were treated by standard percutaneous coronary intervention techniques with IVUS. Operators were allowed to use IVUS information for stent optimization with postdilatation strategies left to their discretion. DM was defined as a history of DM requiring current treatment with insulin, oral agents, and/or dietary therapy. Patients treated with ZoMaxx and double dose sirolimus-eluting stents were excluded. The protocol was approved by the institutional review board, and written informed consent was obtained from each patient.
Intravascular Ultrasound Analysis
A follow-up IVUS examination was prospectively scheduled for all patients involved in the present study, regardless of symptoms, as part of the clinical research protocols. The IVUS procedure was performed in standard fashion at baseline and at 6-to 9-month follow-up, using automated motorized pullback (0.5 mm/s) with commercially available imaging systems (40-MHz IVUS catheter from Boston Scientific Corp, Natick, MA or 20-MHz IVUS catheter from Volcano Corp., Rancho Cordova, CA). IVUS analysis was done in an independent core laboratory at Stanford University (Cardiovascular Core Analysis Laboratory, Stanford, CA). Intraobserver variability has been reported previously. 20 Volumetric IVUS analysis was performed using computer software (echoPlaque, Indec System Inc, Santa Clara, CA), as previously described. 20 Each volume was divided by the measurement of stent length to adjust for different stent lengths (volume index: VI, mm 3 /mm). The percent change in each parameter was calculated as follow-up minus baseline divided by baseline. To evaluate the overall magnitude of neointimal suppression, neointimal obstruction was calculated as neointima volume divided by stent volume. To assess the most severe impact of neointima on luminal encroachment, cross-sectional narrowing (CSN, %) was defined as neointimal area divided by stent area. Cases with CSN>60%, which correspond to 75% stenosis in diameter basis, were described as IVUS-defined restenosis. 15 Moreover, longitudinal severities of lumen encroachment by neointima were also assessed by neointimal hyperplasia 50. Neointimal hyperplasia 50 was defined as percent stent length with percent neointimal area >50%. 21 Plaque burden at reference segment was calculated as (plaque volume/vessel volume) ×100.
Statistical Analysis
Continuous variables are expressed as mean±SD. Categorical data were compared by χ 2 analysis or Fisher exact test. Differences between groups were analyzed by the unpaired Student's t test. The difference of the frequency distribution of between DM and non-DM was tested by the Kolmogorov-Smirnov test. The effects of DM on neointimal proliferation and serial vessel response were evaluated by analysis of covariance, with gender, hypertension, hyperlipidemia, prereference diameter, maximum balloon diameter, and DES type included as potentially confounding variables. Univariate and multivariate linear regression analyses were performed to detect factors that influenced lumen VI at follow-up in both stented and reference segments. Univariate predictors with a P value <0.1 were entered into the multivariate model. A P value <0.05 was considered statistically significant. Stat View 5.0 (SAS Institute, Cary, NC) was used for data analysis.
Results
Baseline Characteristics
A total of 971 patients (267 with DM and 704 without DM) met the enrollment criteria. Follow-up volumetric analysis was available in all 971 patients, and serial volumetric analyses were available in 663 patients (188 with DM and 475 without DM). Overall baseline characteristics for this population are shown in Table 1 . The DM group had significantly fewer males, higher hypertension, and higher hyperlipidemia rates than the non-DM group. As for angiographic findings, the DM group had significantly smaller preprocedure reference diameter, smaller maximum
WHAT IS KNOWN
• When treated with bare metal stents, patients with diabetes mellitus are at particularly greater risk for restenosis and repeat revascularization procedures than nondiabetic patients.
• The primary mechanism for this increased restenosis is exaggerated neointimal hyperplasia.
• The use of drug-eluting stents in percutaneous coronary interventions has reduced neointimal hyperplasia and improved outcomes in the treatment of coronary artery disease across many patient populations, including those with diabetes mellitus.
WHAT THE STUDY ADDS
• The results of the current intravascular ultrasound study add further concept that the use of drug-eluting stents can minimize the differences in vessel responses in both in-stent and reference segments between diabetic and nondiabetic lesions, regardless of the stent type.
• In the drug-eluting stent era, the follow-up lumen up to 6 to 9 months in diabetic patients seems to be determined primarily by the smaller lumen at postprocedure rather than exaggerated neointimal hyperplasia within the stent or plaque proliferation at the reference segments.
balloon size, and smaller stent size than the non-DM group. Stent type was also significantly different between the 2 groups.
Vessel Response Within Stented Segment
The results of IVUS analysis within the stents are shown in Tables 2 and 3 . Regarding each DES, neointimal obstruction was not significantly different between DM and non-DM. Also, there was no interaction between DM and DES type ( Figure 1 ). Overall neointimal obstruction, maximum CSN, and neointimal hyperplasia 50 were not significantly different between the 2 groups with no interaction for the DES type (neointimal obstruction: 11.4±10.7% versus 12.2±10.6%; P=0.76, maximum CSN: Figure 2 ). At postprocedure, overall lumen VI was significantly smaller in DM than in non-DM (6.7±1.8 versus 7.2±2.1 mm3/mm; P=0.0079), whereas vessel VI and peri-stent plaque VI were similar between the 2 groups at postprocedure. At follow-up, similar IVUS findings were observed. Consequently, lumen VI was smaller in DM than in non-DM at follow-up.
Overall percentage change in lumen VI and percentage change in stent VI, indicating chronic stent recoil, were not significantly different between the 2 groups (% change in stent VI: 0.9±6.5% versus 1.1±8.3%; P=0.21).
Vessel Response at Reference Segment
The IVUS findings in reference segments are shown in Table 4 . In the proximal reference segments, residual plaque burden at postprocedure was significantly greater in DM than in non-DM (46.9±9.1% versus 43.8±10.4%; P=0.0001). In the distal reference segments, vessel VI at postprocedure was similar between the 2 groups, and lumen VI at postprocedure was significantly smaller in DM than non-DM, resulting from residual plaque burden at postprocedure being significantly greater in DM than in non-DM (40.1±12.7% versus 37.0±11.2%; P=0.0009). At follow-up, similar IVUS findings were observed. Consequently, the residual plaque burden at postprocedure was significantly greater in DM than in non-DM at both reference segments. Percent changes in vessel VI, lumen VI, and residual plaque burden were similar between the 2 groups at both reference segments. The vessel responses at the reference segments also showed no interaction for the DES type.
Factors Associated With Follow-up Lumen Within Stented Segment
Regarding stented segment, multiple linear regression analysis, including lumen VI at postprocedure, neointimal obstruction, maximum balloon size, maximum balloon pressure, prereference diameter, hypertension, male gender, and DM, as covariates, confirmed that lumen VI at postprocedure, neointimal obstruction, prereference diameter, maximum balloon size, and maximum balloon pressure were independently associated with lumen VI at follow-up. The standardized partial regression coefficient (standardized β) of lumen VI at postprocedure was the highest among independent variables included ( 
Factors Associated With Follow-up Lumen at Reference Segment
Regarding reference segments, additional multiple linear regression analyses, including baseline and procedural characteristics, quantitative coronary angiography, and IVUS variables, as covariates, confirmed that proximal reference lumen VI at postprocedure was independently associated with lumen VI at follow-up. Similarly, multiple linear regression analysis confirmed that distal reference lumen VI at postprocedure was independently associated with distal lumen VI at follow-up. Each standardized β of proximal and distal reference lumen VI at postprocedure was the highest among independent variables included (Table 5) .
Diabetes Treatment
To evaluate the potential influence of diabetes treatment on vessel response, all comparisons were replicated by including medically (insulin and/or oral agents) treated DM patients alone (excluding DM patients with diet-only therapy). The results remained consistent regardless of the need for the medical diabetes treatment ( Table I-V in the online-only Data Supplement).
Discussion
The main findings of this IVUS analysis are as follows: (1) At postprocedure, in-stent lumen VI was significantly smaller and reference segment residual plaque was significantly greater in DM patients than in non-DM patients; (2) At follow-up, crosssectional and longitudinal severities of lumen encroachment by neointima, as well as the overall magnitude of neointimal volume, and plaque proliferation in reference segments were not significantly different between the 2 groups with no interaction for the type of DES; and (3) Consequently, instent lumen VI was smaller and residual plaque was greater in DM than in non-DM at follow-up because of similar vessel response between the 2 groups.
Vessel Response in Diabetes Versus Nondiabetes
In the BMS era, in addition to smaller vessels, neointimal proliferation was greater in patients with DM than in those without DM. 22 Therefore, exaggerated neointimal hyperplasia might have a more significant effect on clinical restenosis in DM patients than in non-DM patients. In our study, once DES attenuated the excess risk of exaggerated neointimal hyperplasia in DM patients, the impact of stent underexpansion became magnified. The stent expansion may have been influenced by potential differences in plaque morphology between the DM and non-DM patients. Although systematic IVUS evaluation of preinterventional plaque morphology was not available in this study, angiographic ACC/AHA lesion classifications were similar between the DM and non-DM patients. Nevertheless, denser tissue matrix of atherosclerotic plaque and greater stiffness of the vessel wall in the DM patients may have impeded adequate stent expansion during stent implantation. 23 Additionally, DM patients more often have smaller reference vessels because of diffuse atherosclerosis and inadequate compensatory remodeling. [24] [25] [26] These plaque characteristics, coupled with smaller, less compliant reference vessels may be responsible for the smaller lumen area at postprocedure in DM patients. In this study, mechanical factors, such as lumen area at postprocedure, maximum balloon diameter, and maximum balloon pressure were independently associated with in-stent follow-up lumen, and the association of lumen area at postprocedure with the follow-up lumen in both in-stent and reference segments seemed to be the strongest, as assessed from the t statistic value in the multiple regression analysis. These findings highlight the critical value and impact of procedural aspects regarding stent deployment, such as stent underexpansion, geographic miss, and incomplete lesion coverage by stents, to subsequent follow-up lumen dimension in DM patients after DES implantation. However, it tends to be more difficult to find an optimal landing zone by angiography, which may be primarily because of the diffuse nature of atherosclerosis in DM patients. Therefore, in the DES era, integrated therapeutic strategies including adjunctive stent dilatation and quantitative assessment of optimal stent landing zone through IVUS guidance may translate to improved lumen patency in both in-stent and reference segments at follow-up in DM patients.
Vessel Response and Target Lesion Revascularization in Diabetes Versus Nondiabetes
Several reports focusing on diabetes and DES have had varied results with respect to angiographic outcome and adverse clinical outcomes. 27 Although DM patients had a greater risk of myocardial infarction, thrombotic complications, and death than non-DM patients, even when treated with DES, DES reduced the risk of in-stent restenosis and target lesion revascularization, regardless of diabetic status. 28, 29 However, in another study, DM had been independently associated with an increased risk of instent restenosis, target lesion revascularization, or target vessel revascularization. 30 In our study, DES attenuated the excess risk of exaggerated neointimal proliferation even in DM patients in stented lesion, and a similar vessel response was observed between DM and non-DM patients in both reference segments. Therefore, this evidence may raise the possibility that the impact of diabetes on in-stent restenosis and target lesion revascularization after DES implantation is minimal as compared with BMS. In general, however, DM patients often present unfavorable coronary anatomy with small and diffusely diseased vessels. 31 Indeed, in this study, DM patients had greater residual plaque burden throughout the reference segment in addition to postprocedure smaller lumen within the stent compared with non-DM patients, indicating the risk for undersize or underexpansion of the stent exists, whereby both may increase stent-related complications. Moreover, previous IVUS studies suggested that greater residual plaque burden at reference vessel segments was associated with edge stenosis in the SES, PES, and BMS cohort. 32, 33 From these findings, in-segment restenosis may be frequently exhibited in DM, which may confer that DM is still one of the risk factors for target lesion revascularization, even in the DES era, as described in some studies.
Vessel Response and Adverse Clinical Outcomes in Diabetes Versus Nondiabetes
Previous IVUS studies suggested that atherosclerotic plaque burden and its progression were associated with adverse cardiovascular events. 34 In this study, DM exhibited greater percent plaque burden throughout the reference segments as compared with non-DM patients. Therefore, it is important to note that greater atherosclerotic plaque burden may be associated with the likelihood of having an increased risk of adverse clinical events in DM patients. Eventually, other factors, such as plaque progression at the new lesion, 35 multivessel disease, and extracardiac disease complications may contribute to higher mortality and target vessel failure rates in patients with DM as compared with non-DM. Therefore, even if DES might have reduced the impact of DM on clinical events within stented segment, such as target lesion revascularization, through the attenuation of neointimal proliferation, DM progression may remain still at high risk.
Study Limitations
Several limitations should be noted. First, this is a retrospective study derived from pooled analyses of randomized control trials, raising a possibility of selection bias. In addition, the current study population comprised patients with a limited range of lesion complexity, and might not reflect a real-world population. Second, data regarding detailed medical treatment information and severity of DM status were limited given that the initial DES trials were not designed to assess the impact of DM on vessel response. Third, the follow-up period of this study was limited to 9 months. All patients had follow-up IVUS at 8 to 9 months, except for those patients enrolled from the DDD trial (followed at 6 months). Fourth, IVUS might not have been performed in cases with severe stenosis or small vessels because of inherent limitations of catheter-based imaging. However, the drop-off rates of IVUS during the angiographic follow-up were similar between DM and non-DM patients (9.5% versus 8.3%, respectively, P=0.44). Moreover, the histogram of neointima (below the critical threshold) showed no deviation in DM compared with non-DM by the Kolmogorov-Smirnov test (Figure 2) . Fifth, preinterventional IVUS data were unavailable for analysis, because of the limitations inherent to the pooled analysis of the clinical trials.
Conclusion
In this analysis of pooled prospective multicenter trials, DM and non-DM lesions showed similar vessel responses in both in-stent and reference segments, regardless of the DES type. In the DES era, the follow-up lumen up to 6 to 9 months in DM patients seems to be determined primarily by the smaller lumen at postprocedure rather than exaggerated neointimal hyperplasia within the stent or plaque proliferation at the reference segments. Thus, IVUS-guided percutaneous coronary intervention may be encouraged to assure adequate stent expansion in DM patients. Further studies are required to confirm this hypothesis for patients with DM in a real-world population.
